The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer

Jun Miyazaki, Koji Kawai, Hitoshi Hayashi, Mizuki Onozawa, Sadamu Tsukamoto, Naoto Miyanaga, Shiro Hinotsu, Toru Shimazui, Hideyuki Akaza

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Combination chemotherapy of methotrexate, actinomycin D and cisplatin (MAP) is reported to be effective against gestational choriocarcinoma. Methods: Eight patients with metastatic testicular cancer who had elevated β-hCG were treated with MAP. They included three refractory cases and two relapsed cases. An additional three patients received MAP as part of the induction therapy. The MAP therapy consisted of methotrexate (10 mg/m2) on days 1-5, actinomycin D (0.01 mg/kg) on days 1-5 and cisplatin (70 mg/m2) on day 1. Results: In all three refractory patients, MAP failed to achieve tumor marker normalization. However, the elevated tumor markers normalized after MAP in the two cases of relapse. Of these two, one patient relapsed again 7 months after MAP and was subsequently salvaged with high-dose chemotherapy. The other patient relapsed and died of the disease 30 months after receiving MAP. Of the three patients who received MAP as part of the induction chemotherapy, one with pure choriocarcinoma achieved tumor marker normalization after MAP and is still alive without disease progression. In the other two patients, MAP failed to achieve marker normalization and the patients received high-dose chemotherapy. The toxicities were mainly bone marrow suppression and mucositis, which were almost acceptable. Conclusions: The results demonstrated the limited efficacy of MAP as salvage therapy. In addition, the efficacy of MAP as part of induction chemotherapy was negligible. However, there might be some role for MAP as a salvage therapy for patients with pure choriocarcinoma.

Original languageEnglish
Pages (from-to)391-395
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume33
Issue number8
DOIs
Publication statusPublished - Aug 1 2003
Externally publishedYes

Fingerprint

Testicular Neoplasms
Dactinomycin
Methotrexate
Cisplatin
Choriocarcinoma
Tumor Biomarkers
Salvage Therapy
Induction Chemotherapy
Drug Therapy
Mucositis
Combination Drug Therapy
Disease Progression
Bone Marrow
Recurrence
Therapeutics

Keywords

  • Actinomycin
  • Cisplatin
  • Methorexate
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology

Cite this

The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer. / Miyazaki, Jun; Kawai, Koji; Hayashi, Hitoshi; Onozawa, Mizuki; Tsukamoto, Sadamu; Miyanaga, Naoto; Hinotsu, Shiro; Shimazui, Toru; Akaza, Hideyuki.

In: Japanese Journal of Clinical Oncology, Vol. 33, No. 8, 01.08.2003, p. 391-395.

Research output: Contribution to journalArticle

Miyazaki, J, Kawai, K, Hayashi, H, Onozawa, M, Tsukamoto, S, Miyanaga, N, Hinotsu, S, Shimazui, T & Akaza, H 2003, 'The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer', Japanese Journal of Clinical Oncology, vol. 33, no. 8, pp. 391-395. https://doi.org/10.1093/jjco/hyg074
Miyazaki, Jun ; Kawai, Koji ; Hayashi, Hitoshi ; Onozawa, Mizuki ; Tsukamoto, Sadamu ; Miyanaga, Naoto ; Hinotsu, Shiro ; Shimazui, Toru ; Akaza, Hideyuki. / The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer. In: Japanese Journal of Clinical Oncology. 2003 ; Vol. 33, No. 8. pp. 391-395.
@article{b99489ec4b474fab9923ca099c64cffa,
title = "The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer",
abstract = "Background: Combination chemotherapy of methotrexate, actinomycin D and cisplatin (MAP) is reported to be effective against gestational choriocarcinoma. Methods: Eight patients with metastatic testicular cancer who had elevated β-hCG were treated with MAP. They included three refractory cases and two relapsed cases. An additional three patients received MAP as part of the induction therapy. The MAP therapy consisted of methotrexate (10 mg/m2) on days 1-5, actinomycin D (0.01 mg/kg) on days 1-5 and cisplatin (70 mg/m2) on day 1. Results: In all three refractory patients, MAP failed to achieve tumor marker normalization. However, the elevated tumor markers normalized after MAP in the two cases of relapse. Of these two, one patient relapsed again 7 months after MAP and was subsequently salvaged with high-dose chemotherapy. The other patient relapsed and died of the disease 30 months after receiving MAP. Of the three patients who received MAP as part of the induction chemotherapy, one with pure choriocarcinoma achieved tumor marker normalization after MAP and is still alive without disease progression. In the other two patients, MAP failed to achieve marker normalization and the patients received high-dose chemotherapy. The toxicities were mainly bone marrow suppression and mucositis, which were almost acceptable. Conclusions: The results demonstrated the limited efficacy of MAP as salvage therapy. In addition, the efficacy of MAP as part of induction chemotherapy was negligible. However, there might be some role for MAP as a salvage therapy for patients with pure choriocarcinoma.",
keywords = "Actinomycin, Cisplatin, Methorexate, Testicular cancer",
author = "Jun Miyazaki and Koji Kawai and Hitoshi Hayashi and Mizuki Onozawa and Sadamu Tsukamoto and Naoto Miyanaga and Shiro Hinotsu and Toru Shimazui and Hideyuki Akaza",
year = "2003",
month = "8",
day = "1",
doi = "10.1093/jjco/hyg074",
language = "English",
volume = "33",
pages = "391--395",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer

AU - Miyazaki, Jun

AU - Kawai, Koji

AU - Hayashi, Hitoshi

AU - Onozawa, Mizuki

AU - Tsukamoto, Sadamu

AU - Miyanaga, Naoto

AU - Hinotsu, Shiro

AU - Shimazui, Toru

AU - Akaza, Hideyuki

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: Combination chemotherapy of methotrexate, actinomycin D and cisplatin (MAP) is reported to be effective against gestational choriocarcinoma. Methods: Eight patients with metastatic testicular cancer who had elevated β-hCG were treated with MAP. They included three refractory cases and two relapsed cases. An additional three patients received MAP as part of the induction therapy. The MAP therapy consisted of methotrexate (10 mg/m2) on days 1-5, actinomycin D (0.01 mg/kg) on days 1-5 and cisplatin (70 mg/m2) on day 1. Results: In all three refractory patients, MAP failed to achieve tumor marker normalization. However, the elevated tumor markers normalized after MAP in the two cases of relapse. Of these two, one patient relapsed again 7 months after MAP and was subsequently salvaged with high-dose chemotherapy. The other patient relapsed and died of the disease 30 months after receiving MAP. Of the three patients who received MAP as part of the induction chemotherapy, one with pure choriocarcinoma achieved tumor marker normalization after MAP and is still alive without disease progression. In the other two patients, MAP failed to achieve marker normalization and the patients received high-dose chemotherapy. The toxicities were mainly bone marrow suppression and mucositis, which were almost acceptable. Conclusions: The results demonstrated the limited efficacy of MAP as salvage therapy. In addition, the efficacy of MAP as part of induction chemotherapy was negligible. However, there might be some role for MAP as a salvage therapy for patients with pure choriocarcinoma.

AB - Background: Combination chemotherapy of methotrexate, actinomycin D and cisplatin (MAP) is reported to be effective against gestational choriocarcinoma. Methods: Eight patients with metastatic testicular cancer who had elevated β-hCG were treated with MAP. They included three refractory cases and two relapsed cases. An additional three patients received MAP as part of the induction therapy. The MAP therapy consisted of methotrexate (10 mg/m2) on days 1-5, actinomycin D (0.01 mg/kg) on days 1-5 and cisplatin (70 mg/m2) on day 1. Results: In all three refractory patients, MAP failed to achieve tumor marker normalization. However, the elevated tumor markers normalized after MAP in the two cases of relapse. Of these two, one patient relapsed again 7 months after MAP and was subsequently salvaged with high-dose chemotherapy. The other patient relapsed and died of the disease 30 months after receiving MAP. Of the three patients who received MAP as part of the induction chemotherapy, one with pure choriocarcinoma achieved tumor marker normalization after MAP and is still alive without disease progression. In the other two patients, MAP failed to achieve marker normalization and the patients received high-dose chemotherapy. The toxicities were mainly bone marrow suppression and mucositis, which were almost acceptable. Conclusions: The results demonstrated the limited efficacy of MAP as salvage therapy. In addition, the efficacy of MAP as part of induction chemotherapy was negligible. However, there might be some role for MAP as a salvage therapy for patients with pure choriocarcinoma.

KW - Actinomycin

KW - Cisplatin

KW - Methorexate

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=30844463229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30844463229&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyg074

DO - 10.1093/jjco/hyg074

M3 - Article

VL - 33

SP - 391

EP - 395

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 8

ER -